Ibrahim Azar, MD
@ibrahimazaronc
Followers
937
Following
6K
Media
77
Statuses
1K
Medical Oncologist @IHACares Assistant Professor @WayneState. Alum @karmanoscancer @AlbanyMed @mcgillu. AΩA. GI Oncology Mednet Associate Editor.
Joined December 2018
Safety, Feasibility, and Patient Experience of Ten-Minute Pembrolizumab Infusions: A Prospective Cohort Study |@JCO_ASCO
ascopubs.org
PURPOSERising cancer incidence and staff shortages demand more efficient outpatient oncology workflows. Pembrolizumab is conventionally administered over 30 minutes. This prospective study assessed...
0
3
13
Andexanet alfa pulled from the US market. This drug, that cost at ~$20k a dose, never showed real benefit, and caused stroke. The story is a fascinating example of misguided ethical thinking, and the human weakness for the power of narrative. This is a wild ride, get ready. 🧵
5
87
336
Today’s approval of our sub-q treatment for EGFR-mutated #NSCLC raises the standard for what patients and their loved ones can expect from the treatment experience. Proud of the @JNJInnovMed team and what this means for patients. Learn more: https://t.co/F4YDuTtDao
#JNJOncology
0
5
16
"Productivity, I’ve come to see, is not measured only by research papers and grants. It is also sustained by presence, rest, and the relationships that give meaning to the work." #ScienceWorkingLife
https://t.co/wdvcDr1qMt
7
263
1K
Why Induction Should Be Performed With T-DXd + Pertuzumab (IMO) The key distinction of DESTINY-Breast09 compared with HER2CLIMB-05 and PATINA is randomization at true treatment initiation. In both HER2CLIMB-05 and PATINA, only patients who did not progress during THP induction
Great news💫 T-DXd plus pertuzumab has been approved by the FDA as a first-line treatment for HER2-positive mBC
4
28
87
TDXd + Pertuzumab now @US_FDA ✅ in 1L metastatic Her2+ breast cancer based off #DestinyBreast09: vs THP: - mPFS 40.7 vs 26.9mos (HR: 0.56) - 15.2% vs 8.5% CRs - Serious TAES: 27% vs 25.1%. Any Gr ILD 12.1% vs 1%. 2 Gr5 ILDs! #OncTwitter #bcsm @OncoAlert @OncUpdates
1
57
125
⭐️ Congrats to @KelseyNatsuhara on her real-world analysis T-DXd rechallenge after grade 1 ILD @UCSFCancer 🔹High rates of rechallenge among grade 1 ILD with low rates of recurrent ILD (32%) and all low grade (1-2). No grade 5 events w/ rechallenge 🔹In blinded imaging review,
3
9
44
😮 Wow, how horrible. Significantly reduced lifespan. Not even just breast cancer, have to focus on how we can reduce all cause mortality for pts who harbor BRCA alterations! Oophorectomy, for example, increases comorbidity and death risk with early menopause. #SABCS25
5
19
54
Hot take: A lot of AI health tech companies are ultimately going to fail because they are going after the WRONG problem. "AI doctors" are just a misguided (but flashy and attractive) solution in search of a problem. An "AI doctor" to "replace your doctor" will never work,
37
27
153
#SABCS25 A few comments on DESTINY-Breast09, PATINA, and HER2CLIMB-05 highlight how differences in trial design and patient selection shape the interpretation of their outcomes. DB-09 randomizes patients at true first-line entry, capturing the full heterogeneity of
1
32
78
One of the most critical aspects of modern care for myeloma patients is providing adequate IgG replacement, particularly for those treated with bispecific antibodies and CAR-Ts. My thoughts and recommendations are below. https://t.co/6MO63sNsLt
4
23
77
Every academic oncologist should spend 1 week seeing patients in the community. I suspect after this experience their research ideas may change to things that are more practical and doable in the real world.
18
37
364
#ASH25 MajesTEC-3 will transform #MMsm care even more than CAR-T for many 🌏 pts in near future. But to shout (again) from rooftop: to do tec-dara safely, use primary IVIG/SCIG prophylaxis! Excellent suppl fig in @NEJM illustrating why OS curves crossed and how they fixed it.
#ASH25 saying it louder for everyone in the back! If you are starting a bsAb in #MMsm (especially BCMA), don’t wait for patient to die or IgG to drop. Start IgRT now! Newest case in point: excellent IFM 2021-01 trial. Only 14% Gr3+ infxns despite older pts & CD38 pair!
3
16
36
7 days for a manuscript review with AI + human @NEJM_AI
ai.nejm.org
This issue of NEJM AI features the first two articles published through our accelerated human+AI review process. In this editorial, we describe the invitation-only “Fast Track” process used to revi...
4
16
77
Nivo avd for all. Not sure why we are not unifying HL early and advanced stage HL. I would want to give farewell to bleo and RT in early stage! #ASH25
2
15
55
In line with the suggestion by @Rfonsi1 Best to consider Tex-Dara as a triplet. It’s Tec-Dara-Ig We need the routine monthly IVIG for safety. @End_myeloma @YiLinMDPhD @TomBmt133
0
7
35
Trainees beware🚨Meetings like #ASH25 are high-density environments of social validation and external rewards. Extrinsic goals provide temporary satisfaction, undermine autonomy and have negative psychological effects! Instead focus on intrinsic goals like personal growth,
7
17
144
Highlights from #ASH25 #CommunityOnc: #Lymphoma 1. #EPCOREFL1 FL 2. #CLL17 CLL 3. #BRUIN313/314 CLL 4. #S1826 HL #Myeloma 5. #COBRA 6. #MajesTEC3 7. #AQUILA 8. #RedirecTT1
#Leukemia 9. #PARADIGM
@ASH_hematology #lymsm #mmsm #HemeTwitter 1/10
1
61
157
💫Missed @ASCOTECAG #Trainee & Early Career #Oncologist Lounge sessions #ASCO25? We turned key panels into editorials so everyone can easily access expert professional development insights! 🔶Series overview https://t.co/vpSdbN2d0j by @NazliDizman
@ASCO #MedEd #ASCO26 @ASCOPres
1
27
40
💫 Excellent overview by @RohitBanwar on practical advice from leaders re building skills & thriving early in your oncology career @ElisaAgostinett @TimothyJBrownMD @AlhajMoustafa @minasedrakmd
@tobechukwuokobi. 🔶 https://t.co/QhD9eNtE9Q
#ASCO26 #ASCO25 @ASCO #MedEd #OncTwitter
1
9
14